CD28 and mantle cell lymphoma: Several studies have explored the clinical application of 4-1BB G3 CAR-T cells, with a small trial in four relapsed indolent B cell or mantle cell lymphoma (MCL) patients to test the safety of CD20-targeting CD28 and 4-1BB G3 CAR-T cells that were already reported in 2012 [53].